# US 2013/0156832 A1 · Eudermic compositions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156832 A1 - Document ID: US20130156832A1 - Status: Published application - Kind: A1 - Application number: 13/702,250 - Filed: 2011-07-12 - Published: 2013-06-20 - Earliest claimed: 2010-07-14 - Assignees: Miso S.r.I. - Inventors: Barbara Onida; Renato Silvio Mortera - Web page: https://patentgrep.com/patent/US20130156832A1 ## CPC - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 8/0208: {Tissues; Wipes; Patches} - A61K 8/25: Silicon; Compounds thereof - A61K 8/368: with carboxyl groups directly bound to carbon atoms of aromatic rings - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 9/5115: {Inorganic compounds} - A61K 31/60: Salicylic acid; Derivatives thereof - A61K 47/02: Inorganic compounds - A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide} - A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) - A61Q 19/00: Preparations for care of the skin - A61K 2800/413: Nanosized, i.e. having sizes below 100 nm - B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery - Y10S 977/814: Group IV based elements and compounds, e.g. CxSiyGez, porous silicon - Y10S 977/906: Drug delivery - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract Eudermic composition comprising at least one eudermically active principle, at least one vehicle for said active principle, and porous silica particles, wherein the active principle is contained in at least one pore of at least a first portion of such silica particles and in the vehicle. ## Claims ### Claim 1 Eudermic composition comprising: at least one eudermically active principle, at least one vehicle for said active principle, and porous silica particles, wherein said active principle is contained in at least one pore of at least a first portion of said silica particles and in said vehicle. ### Claim 2 (depends on 1) Eudermic composition according to claim 1, comprising at least a further vehicle. ### Claim 3 (depends on 1) Eudermic composition according to claim 1, wherein the porous silica particles are silica particles having sub-micrometric sizes, and wherein the pores of said silica particles have a size comprised in the range 2 nm to 50 nm. ### Claim 4 (depends on 1) Eudermic composition according to claim 1, wherein said active principle is contained in said vehicle at a concentration equal to its saturation concentration in said vehicle. ### Claim 5 (depends on 1) Eudermic composition according to claim 1, wherein said active principle contained in said first portion of said porous silica particles is present in an amount comprised in the range 10% to 50% by weight of said portion. ### Claim 6 (depends on 2) Eudermic composition according to claim 2, wherein said active principle is insoluble or poorly soluble in said at least a further vehicle. ### Claim 7 (depends on 2) Eudermic composition according to claim 2, wherein said composition comprises, in addition, at least a further eudermically active principle, said further active principle being contained in at least one pore of a second portion of said silica particles and in said at least a further vehicle, said further active principle being soluble in said at least a further vehicle. ### Claim 8 (depends on 7) Eudermic composition according to claim 7, wherein said further active principle is contained in said at least a further vehicle at a concentration equal to its saturation concentration in said at least a further vehicle. ### Claim 9 (depends on 7) Eudermic composition according to claim 7, wherein said at least a further active principle is insoluble or poorly soluble in said vehicle for said active principle. ### Claim 10 (depends on 1) Eudermic composition according to claim 1, wherein said vehicle and said at least a further vehicle are an hydrophilic vehicle and/or a lipophilic vehicle. ### Claim 11 (depends on 1) Eudermic composition according to claim 1, wherein said active principle and/or at least a further active principle is steadily released over a period of time between 1 and 10 days. ### Claim 12 (depends on 1) Eudermic composition according to claim 1, wherein said eudermic composition is a dermatological composition or a cosmetic composition. ### Claim 13 (depends on 1) Eudermic composition according to claim 1, wherein said eudermic composition is in the form of cream, pomade, ointment, gel, paste. ### Claim 14 (depends on 1) Eudermic composition according to claim 1, wherein said eudermic composition is contained in a transdermal system release. ### Claim 15 (depends on 1) Eudermic composition according to claim 1 for use in the eudermic treatment of the skin.